Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Assesment of Treatment Outcomes of Aquired Aplastic Anemia in Children : A Retrospective and Prospective Cohort

NCT07131878 ·Status: NOT_YET_RECRUITING

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients

NCT03877809 ·Status: COMPLETED ·Phase: PHASE2

Clinical Characteristics and Treatment Outcomes of Patients With Autoimmune Hemolytic Anemia

NCT03269292 ·Status: COMPLETED

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

NCT05073458 ·Status: TERMINATED ·Phase: PHASE3

Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05221619 ·Status: TEMPORARILY_NOT_AVAILABLE

Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.

NCT01579110 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

NCT05786573 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

NCT00006136 ·Status: COMPLETED ·Phase: PHASE2

Study of Acquired Hemolytic Anemia in Adult Hospitalized Patients

NCT06708728 ·Status: NOT_YET_RECRUITING

Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)

NCT01760096 ·Status: UNKNOWN ·Phase: PHASE2

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04661033 ·Status: TERMINATED ·Phase: PHASE2

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918 ·Status: COMPLETED ·Phase: PHASE3

Tacrolimus Treatment for Refractory PRCA

NCT03540472 ·Status: UNKNOWN ·Phase: PHASE4

The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment

NCT04814394 ·Status: NOT_YET_RECRUITING

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668 ·Status: TERMINATED ·Phase: PHASE2

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

NCT00061763 ·Status: COMPLETED ·Phase: PHASE2

Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic Anemia

NCT06743854 ·Status: NOT_YET_RECRUITING

Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major

NCT02342145 ·Status: COMPLETED ·Phase: PHASE4

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

NCT05664737 ·Status: RECRUITING ·Phase: PHASE2

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

NCT06024876 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

NCT03764618 ·Status: COMPLETED ·Phase: PHASE3

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

NCT04610866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3